论文部分内容阅读
比较干扰灵联合抗乙肝免疫核糖核酸与无环鸟苷联合胸腺肽抗乙肝病毒疗效。采用ELISA和PCR法检测慢性乙肝患者治疗前、结束以及治疗后 6mon血清HBsAg、抗 -HBs、HBeAg、抗 -HBe、抗 -HBc以及HBVDNA。治疗结束时 ,干扰灵组HBsAg转阴率 2 0 % (6 /30 )、HBeAg转阴率 6 6 7% (18/2 4)、HBVDNA转阴率 6 0 % (18/30 ) ,随访 6mon 2例HBsAg、HBeAg、HBVDNA复阳、1例HBeAg、HBVDNA转阴 ;无环鸟苷组治疗结束时 ,HBsAg、HBeAg、HBVDNA转阴率分别为 6 1% (2 /33)、5 5 2 %(16 /2 9)、5 4 5 % (18/33) ,随访结束时其转阴率分别为 2 7 3% (9/33)、5 8 6 % (17/2 9)、6 0 6 % (2 0 /33)。两组治疗后及随访期末 ,HBeAg、HBVDNA转阴率均显著高于对照组 (P <0 0 1) ,但两组间比较其转阴率无明显差异 (P >0 0 5 )。两种联合疗法均能显著抑制乙肝病毒复制 ,两种联合疗法疗效基本一致 ,但无环鸟苷联合组疗程短、价廉、远期疗效好。
Comparison of interfering spleen joint anti-hepatitis B immune RNA and acyclovir thymosin combined anti-hepatitis B virus efficacy. The levels of HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc and HBVDNA in 6months of patients with chronic hepatitis B before and after treatment and after treatment were detected by ELISA and PCR. At the end of treatment, HBsAg negative rate 20% (6/30), HBeAg negative rate 6 6 7% (18/2 4) and HBVDNA negative rate 6 0% (18/30) were followed up for 6months 2 cases of HBsAg, HBeAg, HBVDNA complex positive, 1 case of HBeAg, HBVDNA negative; at the end of treatment with acyclovir group, HBsAg, HBeAg, HBVDNA negative rates were 6 1% (2/33), 5 52% (16/29) and 54.5% (18/33), respectively. The rates of negative conversion at the end of follow-up were 273% (9/33), 586% (17/2 9) and 666 % (2 0/33). After treatment and at the end of the follow-up period, the negative conversion rates of HBeAg and HBVDNA in both groups were significantly higher than those in the control group (P <0.01), but there was no significant difference between the two groups (P> 0.05). Both combination therapy can significantly inhibit the replication of hepatitis B virus, the two combination therapy is basically the same efficacy, but the combination of acyclovir treatment group is short, inexpensive, long-term efficacy.